BIONTECH SE SPON. ADRS 1
Commented by Fabian Lorenz on October 16th, 2025 | 07:05 CEST
Takeover fever and AI Opportunities: BioNTech, Novo Nordisk, PanGenomic Health
The pharmaceutical and biotech sector is buzzing with takeover activity. Following the announcement of a billion-dollar acquisition in the US, Novo Nordisk has announced its next deal, eyeing a potential best-in-class therapeutic for several rare diseases. Meanwhile, PanGenomic Health is positioning itself in the billion-dollar market for alternative medicine and dietary supplements, leveraging AI to provide added value to customers and capture market share. If successful, the stock could be significantly undervalued. BioNTech's acquisition of CureVac has now been completed, ending CureVac's period of suffering. In the process, BioNTech secures patents and elegantly resolves ongoing legal disputes.
Read
Commented by Nico Popp on October 16th, 2025 | 07:00 CEST
Who definitely deserves credit in the fight against cancer: NetraMark, Moderna, BioNTech
Two biotech pioneers, Moderna and BioNTech, are back in the spotlight after their COVID-19 vaccine success - this time in a race to develop innovative cancer therapies. Both companies rely on mRNA technology to develop personalized cancer vaccines. Speed is crucial here: whoever brings effective treatments to market first could secure billions in market share. At the same time, AI startup NetraMark is entering the stage with novel data analysis that could significantly accelerate research and shape medical progress. We shed light on what is currently driving both the research community and investors.
Read
Commented by Fabian Lorenz on October 14th, 2025 | 07:30 CEST
Alternative to BioNTech, Evotec, and Co.: BioNxt Solutions impresses at investor conference and sparks takeover speculation
While the shares of BioNTech and Evotec are treading water, BioNxt Solutions is on an upward trajectory. The Company is currently shaking up Big Pharma. The announcement to replace the weight-loss injection Ozempic with an oral dissolvable film has sparked takeover speculation. BioNxt also aims to make waves in multiple sclerosis, another multi-billion-dollar market, by significantly simplifying the administration of a blockbuster drug for patients. At last week's IIF investor conference, the management board delivered a convincing presentation. Partnerships and licensing opportunities were outlined - assuming no acquisition occurs beforehand. This could prove highly rewarding for both a pharmaceutical company and shareholders.
Read
Commented by Armin Schulz on October 7th, 2025 | 07:20 CEST
Cancer research with billion-dollar potential: How Bayer, Vidac Pharma, and BioNTech could come into play
The oncology market is booming like no other. Driven by technological quantum leaps and, unfortunately, rising case numbers, cancer treatment is becoming a highly lucrative innovation engine. The sector is growing at double-digit rates every year. Experts predict that the global market volume will break the USD 1 trillion mark within the next decade. No wonder, then, that the race for the next therapeutic breakthroughs in personalized medicines and AI-supported active ingredients is heating up. Investors are focusing not only on established players like Bayer, but also on up-and-coming specialists such as Vidac Pharma and mRNA pioneers like BioNTech.
Read
Commented by André Will-Laudien on September 29th, 2025 | 07:20 CEST
Attention: Acquisitions! Biotechs like Evotec, PanGenomic Health, Pfizer, and BioNTech in focus
The biotech industry is in turmoil! With the expiration of blockbuster patents, there is a threat of sharp declines in revenue, which must be strategically compensated for. Driven by economic pressure and a growing focus on innovation and technology, the industry is increasingly turning to acquisitions of biotech companies with promising drug candidates, new technologies, and digital expertise. Not only are entire pipelines being acquired, but key players from the fastest-growing segments are also being targeted, particularly in the field of obesity therapies, where billions are being paid for drug candidates. Several examples illustrate this wave of transformation. Companies are restructuring, focusing their activities, and rapidly preparing for a phase of sustainable growth. The pace is picking up! Here are some promising investment ideas!
Read
Commented by Fabian Lorenz on September 18th, 2025 | 07:10 CEST
MAJOR DEVELOPMENTS for megatrend stocks: Rheinmetall, BioNTech, First Hydrogen
Rheinmetall is going full throttle: on land, at sea, in the air, and even in space. Its latest bombshell is the announced takeover of Lürssen's naval division. Will this provide the tailwind the stock needs to break through the EUR 2,000 mark on a sustained basis? Analysts view the transaction positively, though some cautionary voices remain. Meanwhile, a major development in Canada is boosting sentiment around First Hydrogen. North Americans aim to be at the forefront of the small modular reactors (SMRs) movement. The potential is enormous. BioNTech also holds significant promise in the fight against cancer. However, challenges have emerged - ironically in the world's largest pharma market. The US government plans to cut or even stop funding for new mRNA vaccine development. BioNTech shares reacted accordingly and may break through their sideways trend downwards.
Read
Commented by Fabian Lorenz on September 12th, 2025 | 07:15 CEST
200% shares Steyr Motors and PanGenomic Health! When will cancer-fighter BioNTech explode?
More than 200% price gains are not enough: Steyr Motors and PanGenomic Health continue to go full throttle. Despite its strong performance in recent weeks, PanGenomic still appears undervalued. With the use of artificial intelligence, the Canadians want to tap into the billion-dollar market for personalized alternative medicine and dietary supplements in North America. Their e-commerce platform has just gone live. Steyr Motors reports several successes in China, opening up a billion-dollar market for the Austrians. In contrast, BioNTech shares are not moving. Yet the Mainz-based company is increasingly becoming a real cancer fighter. Will the stock soon explode?
Read
Commented by Armin Schulz on September 10th, 2025 | 07:05 CEST
Oncology boom: How Bayer, Vidac Pharma, and BioNTech could outperform with their full pipelines
The oncology industry is facing an unprecedented wave of growth: the global market is expected to double to over USD 866 billion by 2034. Driven by demographic factors, groundbreaking immunotherapies, and a record number of new drugs, investors are facing a historic window of opportunity. Those who invest in the right innovators with bulging pipelines and disruptive technologies can benefit from this mega-trend wave. This is precisely where the promising strategies of Bayer, Vidac Pharma, and BioNTech come in.
Read
Commented by André Will-Laudien on September 9th, 2025 | 10:05 CEST
The next wave is coming! NetraMark and BioNTech are on the winning track - Can Novo Nordisk and Eli Lilly follow suit?
Artificial intelligence (AI) is transforming the development of new drugs by analyzing complex data at lightning speed and making clinical trials more efficient. AI technologies enable candidates to be selected more specifically for research projects and therapeutic successes to be predicted with greater precision. Companies such as NetraMark and BioNTech have already successfully used these tools, with the Mainz-based company currently even achieving breakthroughs in oncology. Meanwhile, Novo Nordisk and Eli Lilly, once stars of the obesity market, are now seen as "fallen angels". Will they manage to turn things around? Investors with foresight now have new opportunities in rapidly growing billion-dollar markets. A long-awaited interest rate cut in the US could be the spark the sector needs! Selection is now key!
Read
Commented by Stefan Feulner on September 8th, 2025 | 07:10 CEST
Opendoor, Almonty Industries, BioNTech – Great opportunities outside the tech bubble
While the Nasdaq 100 continued to lose momentum last week, along with leading tech stocks, the crisis metal gold celebrated a new all-time high at USD 3,586 per ounce. The escalating geopolitical crises and the intensifying trade war between the US and China are likely to drive prices for critical raw materials in the long term. Western producers remain attractively valued.
Read